본문 바로가기
KERD
논문KCI 등재

Graft-versus-Leukemia Effect of Nonmyeloablative Stem Cell Transplantation

Masahiro Imamura|Junji Tanaka
대한내과학회 (The Korean Association Of Internal Medicine)|2009.12|The Korean Journal of Internal Medicine|제24권 제4호|pp. 287-298

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Graft-versus-host diseaseGraft-versus-leukemia effectNonmyeloablative stem cell transplantation
주제분류내과학

초록

Nonmyeloablative stem cell transplantation (NST) is increasingly used with beneficial effects because it can be applied to older patients with hematological malignancies and those with various complications who are not suitable for conventional myeloablative stem cell transplantation (CST). Various conditioning regimens differ in their myeloablative and immunosuppressive intensity. Regardless of the type of conditioning regimen, graftversus- host disease (GVHD) in NST occurs almost equally in CST, although a slightly delayed development of acute GVHD is observed in NST. Although graft-versus-hematological malignancy effects (i.e., graft-versusleukemia effect, graft-versus-lymphoma effect, and graft-versus-myeloma effect) also occur in NST, completely eradicating residual malignant cells through allogeneic immune responses is insufficient in cases with rapidly growing disease or uncontrolled progressive disease. Donor lymphocyte infusion (DLI) is sometimes combined to support engraftment and to augment the graft-versus-hematological malignancy effect, such as the graft-versusleukemia effect. DLI is especially effective for controlling relapse in the chronic phase of chronic myelogenous leukemia, but not so effective against other diseases. Indeed, NST is a beneficial procedure for expanding the opportunity of allogeneic hematopoietic stem cell transplantation to many patients with hematological malignancies. However, a more sophisticated improvement in separating graft-versus-hematological malignancy effects from GVHD is required in the future.

Abstract

Nonmyeloablative stem cell transplantation (NST) is increasingly used with beneficial effects because it can be applied to older patients with hematological malignancies and those with various complications who are not suitable for conventional myeloablative stem cell transplantation (CST). Various conditioning regimens differ in their myeloablative and immunosuppressive intensity. Regardless of the type of conditioning regimen, graftversus- host disease (GVHD) in NST occurs almost equally in CST, although a slightly delayed development of acute GVHD is observed in NST. Although graft-versus-hematological malignancy effects (i.e., graft-versusleukemia effect, graft-versus-lymphoma effect, and graft-versus-myeloma effect) also occur in NST, completely eradicating residual malignant cells through allogeneic immune responses is insufficient in cases with rapidly growing disease or uncontrolled progressive disease. Donor lymphocyte infusion (DLI) is sometimes combined to support engraftment and to augment the graft-versus-hematological malignancy effect, such as the graft-versusleukemia effect. DLI is especially effective for controlling relapse in the chronic phase of chronic myelogenous leukemia, but not so effective against other diseases. Indeed, NST is a beneficial procedure for expanding the opportunity of allogeneic hematopoietic stem cell transplantation to many patients with hematological malignancies. However, a more sophisticated improvement in separating graft-versus-hematological malignancy effects from GVHD is required in the future.

참고문헌 (141)

  1. Giralt S, "Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy", Blood, 89, pp.4531~4536 (1997)
  2. Slavin S, "Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases", Blood, 91, pp.756~763 (1998)
  3. McSweeney PA, "Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graftversus- tumor effects", Blood, 97, pp.3390~3400 (2001)
  4. Spitzer TR, "Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies", Biol Blood Marrow Transplant, 6, pp.309~320 (2000)
  5. Childs R, "Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem celltransplantation: full donor T-cell chimerism precedes alloimmune responses", Blood, 94, pp.3234~3241 (1999)
  6. Kottaridis PD, "In vivo CAMPATH1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation", Blood, 96, pp.2419~2425 (2000)
  7. Bornhauser M, "Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients", Clin Cancer Res, 7, pp.2254~2262 (2001)
  8. Storb R, "Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients", Blood, 59, pp.236~246 (1982)
  9. Sullivan KM, "Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms", N Engl J Med, 320, pp.828~834 (1989)
  10. Kolb H, "Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients", Blood, 76, pp.2462~2465 (1990)
  11. Porter DL, "Induction of graftversus- host disease as immunotherapy for relapsed chronic myeloid leukemia", N Engl J Med, 330, pp.100~106 (1994)
  12. Mackinnon S, "Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease", Blood, 86, pp.1261~1268 (1995)
  13. Andreani M, "Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia", Blood, 87, pp.3494~3499 (1996)
  14. Collins RH Jr, "Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation", J Clin Oncol, 15, pp.433~444 (1997)
  15. Childs R, "Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem-cell transplantation", N Engl J Med, 343, pp.750~758 (2000)
  16. Ueno NT, "Allogeneic peripheralblood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer", J Clin Oncol, 16, pp.986~993 (1998)
  17. Giralt S, "Melphalan and purine analogcontaining preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation", Blood, 97, pp.631~637 (2001)
  18. Chakraverty R, "Limiting transplantationrelated mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen", Blood, 99, pp.1071~1078 (2002)
  19. Bornhauser M, "Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antitymocyte globulin", Bone Marrow Transplant, 26, pp.119~125 (2000)
  20. Saito T, "Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced", refractory acute leukemia, Clin Cancer Res, pp.2002, 8[DOI]
  21. Khouri IF, "Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancie", J Clin Oncol, 16, pp.2817~2824 (1998)
  22. Khouri IF, "Nonablative allogeneic stem-cell transplantation for advanced", recurrent mantle cell lymphoma, 2003, pp.21, 4407~4412
  23. Maris MB, "HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies", Blood, 102, pp.2021~2030 (2003)
  24. Feinstein LC, "Nonmyeloablative allografting from human leukocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission", Br J Haematol, 120, pp.281~288 (2003)
  25. Antin JH, "Cytokine dysregulation and acute graftversus- host disease", Blood, 80, pp.2964~2968 (1992)
  26. Tanaka J, "Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation", Br J Haematol, 85, pp.558~565 (1993)
  27. Imamura M, "Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-γ, and tumor necrosis factor-α in graftversus- host disease", Bone Marrow Transplant, 13, pp.745~751 (1994)
  28. Tanaka J, "The important balance between cytokines derived from type-1 and type-2 helper T cells in the control of graft-versus-host disease", Bone Marrow Transplant, 19, pp.571~576 (1997)
  29. Alyea EP, "Comparative outcome of nonmyeloablative and myeloabltaive allogeneic hematopoietic cell transplantation for patients older than 50 years of age", Blood, 105, pp.1810~1814 (2005)
  30. Valcarcel D, "Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies", Eur J Haematol, 74, pp.144~151 (2005)
  31. Scott BL, "Myeloabltative vs myeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis", Leukemia, 20, pp.128~135 (2006)
  32. Nagler A, "Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma", Bone Marrow Transplant, 25, pp.1021~1028 (2000)
  33. Michallet M, "Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome", J Clin Oncol, 19, pp.3340~3349 (2001)
  34. Baron F, "Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation", J Clin Oncol, 24, pp.4150~4157 (2006)
  35. Baron F, "Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning", J Clin Oncol, 23, pp.1993~2003 (2005)
  36. Maruyama D, "Comparable antileukemia", lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen, 2007, pp.13, 932~941
  37. Hegenbart U, "Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors", J Clin Oncol, 24, pp.444~453 (2006)
  38. Alyea EP, "Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome", Biol Blood Marrow Transplant, 12, pp.1047~1055 (2006)
  39. Estey E, "Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)", Blood, 109, pp.1395~1400 (2007)
  40. Or R, "Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase", Blood, 101, pp.441~445 (2003)
  41. Crawley C, "Outcomes of reducedintensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT", Blood, 106, pp.2969~2976 (2005)
  42. Baron F, "HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia", Biol Blood Marrow Transplant, 11, pp.272~279 (2005)
  43. Martino R, "Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study", Haematologica, 88, pp.555~560 (2003)
  44. Hamaki T, "Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients", Bone Marrow Transplant, 35, pp.549~556 (2005)
  45. Lee S, "Allogeneic stem cell transplantation in first complete remission enhances graft-versusleukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease", Biol Blood Marrow Transplant, 13, pp.1083~1094 (2007)
  46. Imamura M, "Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan", Int J Hematol, 83, pp.164~178 (2006)
  47. Shigematsu A, "Exellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total body irradiation for adult patients with acute lymphoblastic leukemia", Biol Blood Marrow Transplant, 14, pp.568~575 (2008)
  48. Gribben JG, "Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia", Blood, 106, pp.4689~4396 (2005)
  49. Rondon G, "Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia", Bone Marrow Transplant, 18, pp.669~672 (1996)
  50. Dreger P, "Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis", Leukemia, 19, pp.1028~1033 (2005)
  51. Corradini P, "Reduced-intenisty conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poorrisk hematologic malignancies", Blood, 99, pp.75~82 (2002)
  52. Robinson SP, "Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation", Blood, 100, pp.4310~4316 (2002)
  53. Khouri IF, "Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graftversus- host diseases, and transplant-related mortality", Blood, 98, pp.3595~3599 (2001)
  54. Bjorkstrand BB, "Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation", Blood, 88, pp.4711~4718 (1996)
  55. Tricot G, "Graft-versus-myeloma effect: proof of principle", Blood, 87, pp.1196~1198 (1996)
  56. Martinelli G, "Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma", J Clin Oncol, 18, pp.2273~2281 (2000)
  57. Attal M, "Single versus double autologous stem cell transplantation for multiple myeloma", N Engl J Med, 349, pp.2495~2502 (2003)
  58. Cavo M, "Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study", J Clin Oncol, 25, pp.2434~2441 (2007)
  59. Kruger N, "Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma", Blood, 100, pp.755~760 (2002)
  60. Maloney DG, "Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma", Blood, 102, pp.3447~3454 (2003)
  61. Garban F, "Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma", Blood, 107, pp.3474~3480 (2006)
  62. Rajkumar SV, "Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group", J Clin Oncol, 24, pp.431~436 (2006)
  63. Richardson PG, "Bortezomib or high-dose dexamethasone for relapsed multiple myeloma", N Engl J Med, 452, pp.2487~2498 (2005)
  64. Attal M, "Maintenance therapy with tahildomide improves survival in patients with multiple myeloma", Blood, 108, pp.3289~3294 (2006)
  65. Kolb HJ, "Graft-versusleukemia effect of donor lymphocyte transfusions in marrow grafted patients", Blood, 86, pp.2041~2050 (1995)
  66. Porter DL, "Graft-versustumor induction with donor leukocyte infusions as primary therapy for patients with malignancies", J Clin Oncol, 17, pp.1234~ (1999)
  67. Dazzi F, "Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia", Blood, 96, pp.2712~2716 (2000)
  68. Lokhorst HM, "Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation", Blood, 90, pp.4206~4211 (1997)
  69. Salama M, "Donor leukocyte infusions for multiple myeloma", Bone Marrow Transplant, 26, pp.1179~1184 (2000)
  70. Lokhorst HM, "Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome", J Clin Oncol, 18, pp.3031~3037 (2000)
  71. Bardos A, "High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions", Blood, 97, pp.2574~2579 (2001)
  72. Alyea E, "T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graftversus- myeloma effect", Blood, 98, pp.934~939 (2001)
  73. Ratanatharthorn V, "Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma", Blood, 84, pp.1050~1055 (1994)
  74. Jones RJ, "Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation", Blood, 77, pp.649~653 (1991)
  75. Mandigers CM, "Graft versus-lymphoma effect of donor leukocyte infusion shown by real-time quantitative PCR analysis of t(14;18)", Lancet, 352, pp.1522~1523 (1998)
  76. Porter DL, "‘GVHD’: graft-versushost disease or graft-versus-Hodgkin’s disease? An old acronym with new meaning", Bone Marrow Transplanat, 31, pp.739~746 (2003)
  77. Marks DI, "The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation", Blood, 100, pp.3108~3114 (2002)
  78. Bethge WA, "Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopietic cell transplantation following nonmyeloablative conditioning", Blood, 103, pp.790~795 (2004)
  79. Miura Y, "Analysis of donor type chimerism in lineage-specific cell populations after allogeneic myeloablative and nonmyeloablative cell transplantation", Bone Marrow Transplant, 37, pp.837~843 (2006)
  80. Baron F, "Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning", Blood, 104, pp.2254~2262 (2004)
  81. Cudkowicz G, "Peculiar immunobiology of bone marrow allografts: II. Rejection of parental grafts by resistant F1 hybrid mice", J Exp Med, 134, pp.1513~1528 (1971)
  82. Murphy WJ, "Acute rejection of murine bone marrow allografts by natural killer cells and T cells: differences in kinetics and target antigens recognized", J Exp Med, 166, pp.1499~1509 (1987)
  83. Cho SG, "Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation", Exp Hematol, 32, pp.1246~1254 (2004)
  84. Baron F, "Graft-versus-tumor effects after allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning", J Clin Oncol, 23, pp.1993~2003 (2005)
  85. Chan GW, "Persistence of host dendritic cells after transplantation is associated with graftversus- host disease", Biol Bone Marrow Transplant, 9, pp.170~176 (2003)
  86. Chen W, "Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon", Eur J Immunol, 34, pp.194~199 (2004)
  87. Matte CC, "Donor APCs are required for maximal GVHD but not for GVL", Nat Med, 10, pp.987~992 (2004)
  88. Reddy P, "A crucial role for antigenpresenting cells and alloantigen expression in graft-versusleukemia responses", Nat Med, 11, pp.1244~1249 (2005)
  89. Anderson BE, "Distinct roles for donorand host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ", Blood, 105, pp.2227~2234 (2005)
  90. Shlomchik WD, "Prevention of graft versus host disease by inactivation of host antigen-presenting cells", Science, 285, pp.412~415 (1999)
  91. Ruggeri L, "Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants", Science, 295, pp.2097~2100 (2002)
  92. Blazar BR, "vivo blockade of CD28", CTLA4:B7, Blood, pp.1994, 83[DOI]
  93. Blazar BR, "Coblockade of the LFA1:ICAM1 and CD28", CTLA4:B7 pathways is a highly effective means of preventing graft-versushost disease induced by fully major histocompatibility complex-disparate donor grafts, 1995, pp.85, 2607~2618
  94. Blazar BR, "CD28", B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells, 1997, pp.159, 3460~3473
  95. Ohata J, "Differential graft-versusleukaemia effect by CD28 and CD40 costimulatory blockade after graft-versus-host disease prophylaxis", Clin Exp Immunol, 129, pp.61~68 (2002)
  96. Blazar BR, "Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients", Blood, 101, pp.3741~3748 (2003)
  97. Taylor PA, "Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells downregulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM)", Blood, 105, pp.3372~3380 (2005)
  98. Liang Y, "Beta2 integrins separate graftversus- host disease and graft-versus-leukemia effect", Blood, 111, pp.954~962 (2008)
  99. Murai M, "Active participation of CCR5+CD8+ T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease", J Clin Invest, 104, pp.49~57 (1999)
  100. Serody JS, "Panoskaltsis-Mortari A, et al. Tlymphocyte production of macrophage inflammatory protein-1 alpha is critical to the recruitment of CD8+ T cells to the liver, lung, and spleen during graft-versus-host disease", Blood, 96, pp.2973~2980 (2000)
  101. New JY, "T cell infiltration and chemokine expression: relevance to the disease localization in murine graftversus- host disease", Bone Marrow Transplant, 29, pp.979~986 (2002)
  102. Sasaki M J, "Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice", J Immunol, 170, pp.588~596 (2003)
  103. Duffner U, "Role of CXCR3-induced donor T-cell migration in acute GVHD", Exp Hematol, 31, pp.897~902 (2003)
  104. Wysocki CA, "Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease", Blood, 106, pp.3300~3307 (2005)
  105. Wysocki CA, "Leukocyte migration and graft-versus-host disease", Blood, 105, pp.4191~4199 (2005)
  106. Rao AR, "CC chemokine receptor 2 expression in donor cells serves an essential role in graftversus- host disease", J Immunol, 171, pp.4875~4885 (2003)
  107. Terwey TH, "CCR2 is required for CD8-induced graft-versus-host disease", Blood, 106, pp.3322~3330 (2005)
  108. Choi SW, "CCR1", CCL5 (RANTES) receptor-ligand interactions modulate allogeneic Tcell responses and graft-versus-host disease following stem-cell transplantation, 2007, pp.110, 3447~3455
  109. Sun K, "Inhibition of acute graft-versus-host disease with retention of graft-versustumor effects by the proteasome inhibitor bortezomib", Proc Natl Acad Sci U S A, 101, pp.8120~8125 (2004)
  110. Reddy P, "Histon deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemic effect", Proc Natl Acad Sci U S A, 101, pp.3921~3926 (2004)
  111. Ruggeri L, "Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation", Blood, 94, pp.333~339 (1999)
  112. Igarashi T, "Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells", Blood, 104, pp.170~177 (2004)
  113. Miller JS, "Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer", Blood, 105, pp.3051~3057 (2005)
  114. Antin JH, "Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation", Blood, 102, pp.1601~1605 (2003)
  115. Cutler C, "Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation", Biol Blood Marrow Transplant, 10, pp.328~336 (2004)
  116. Hori T, "CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease", Blood, 111, pp.4403~4412 (2008)
  117. Ota Y, "Upregulation of plasma CCL8 in mouse model of graft-versus-host disease", Exp Hematol, 37, pp.525~531 (2009)
  118. Paczesny S, "biomarker panel for acute graft-versus-host disease", Blood, 113, pp.273~278 (2009)
  119. Goulmy E, "Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation", N Engl J Med, 334, pp.281~285 (1996)
  120. Marijit WA, "Hmatopoiesis restricted minor histocompatibility antigens HA- 1- or HA-2specific T cells can induce complete remissions of relapsed leukemia", Proc Natl Acad Sci U S A, 100, pp.2742~2747 (2003)
  121. Spierings E, "Minor histocompatibility antigens: big in tumor therapy", Trends Immunol, 25, pp.56~60 (2004)
  122. Warren EH, "The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen", J Immunol, 164, pp.2807~2814 (2000)
  123. Dickinson AM, "In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens", Nat Med, 8, pp.410~414 (2002)
  124. Zorn, "Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation", J Exp Med, 199, pp.1133~1142 (2004)
  125. Rosinski KV, "DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells", Blood, 111, pp.4817~4826 (2008)
  126. Molldrem JJ, "Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia", Nat Med, 6, pp.1018~1023 (2000)
  127. Molldrem JJ, "Overexpressed diffenerntiation antigens as targets of graft-versus-leukemia reactions", Curr Opin Hematol, 9, pp.503~508 (2002)
  128. Yong AS, "High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cells transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects", Blood, 110, pp.770~775 (2007)
  129. Gao L, "Selective elimination of leukemic CD34+ progenitor cell by cytotoxic T lymphocytes specific for WT1", Blood, 95, pp.2198~2203 (2000)
  130. Gaiger A, "Immunity to WT1 in the animal models and in patients with acute myeloid leukemia", Blood, 96, pp.1480~1489 (2000)
  131. Oka Y, "Human cytotoxic Tlymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product", Immunogenetics, 51, pp.99~107 (2000)
  132. Azuma T, "Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1- specific cytotoxic T lymphocytes", Clin Cancer Res, 10, pp.7402~7412 (2004)
  133. Fukuda S, "Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3", Blood, 114, pp.394~403 (2009)
  134. Reker S, "Identification of novel surviving-derived CTL epitope", Cancer Biol Ther, 3, pp.173~179 (2004)
  135. Ambrosini G, "A novel anti-apoptosis gene, surviving, expressed in cancer and lymphoma", Nat Med, 3, pp.917~921 (1997)
  136. Schwartz J, "Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia", Semin Hematol, 40, pp.87~96 (2003)
  137. Kwak LW, "Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor", Lancet, 345, pp.1016~1020 (1995)
  138. Yotnda P, "Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia", J Clin Invest, 101, pp.2290~2296 (1998)
  139. Yong AS, "Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia associated antigens: implications for the graft-versus-leukemiaeffect and peptide-based immunotherapy", Leukemia, 22, pp.1721~1727 (2008)
  140. Kawase T, "High-risk HLA allele mismatch combinations responsible for severe acute graftversus- host disease and implication for its molecular mechanism", Blood, 110, pp.2235~2241 (2007)
  141. Kawase T, "HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism", Blood, 113, pp.2851~2858 (2009)

관련 논문AI추천

비골수제거성 조혈모세포이식현명수영남대학교 의과대학 · Journal of Yeungnam Medical Science2002 · 제19권 제1호Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantationDajung Kim, Ho-Jin Shin, Ho Sup Lee, Jae-Sook Ahn, Je-Hwan Lee, Joon-Ho Moon, Silvia Park, Taeyun Kim, Won Sik Lee, Yunsuk Choi대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제2호Clinical Utility of Chimerism Status Assessed by Lineage-Specific Short Tandem Repeat Analysis: Experience from Four Cases of Allogeneic Stem Cell Transplantation허경, 고리영, 권혁찬, 김성현, 김효진, 송유정, 오성용, 조성숙, 한진영대한진단검사의학회 · Annals of Laboratory Medicine2009 · 제29권 제4호Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea김세형, 김찬규, 박성규, 안재숙, 원종호, 윤진아, 임성희, 장금하, 지영석연세대학교의과대학 · Yonsei Medical Journal2023 · 제64권 제2호Does anti-thymocyte globulin have a place in busulfan/ fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?김경하, Chang Wook Min, Chan-Kyu Kim, Dae-Sik Hong, Hyun Jung Kim, Jina Yun, Jong-Ho Won, Kyu-Taek Lee, Min Sung Lee, Se Hyung Kim, Seong Kyu Park, Young Sok Ji대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제4호The Impact of HLA and KIR Ligand Mismatching on Unrelated Allogeneic Hematopoietic Stem Cell Transplantation in Korean Adult Patients신수, 김인호, 노은연, 박경운, 박선양, 박혜원, 송은영, 윤성수, 인지원대한진단검사의학회 · Annals of Laboratory Medicine2015 · 제35권 제1호

이 간행물의 다른 논문 (6건)

Comparison of Sirolimus and Paclitaxel-Eluting Stents for Complex Coronary Lesions: An Intravascular Ultrasound Study김현태, 남창욱, 김윤년, 윤혁준, 한성욱, 허승호, 조윤경, 김권배, 김형섭, 김인철, 박형섭pp. 323-329Serum C-Reactive Protein Levels in Normal-Weight Polycystic Ovary Syndrome오지영, 오지영, 이지하, 이혜진, 정혜원, 성연아pp. 350-355Natural History and Renal Pathology in Patients with Isolated Microscopic Hematuria김영옥, 김용수, 김용균, 송호철, 신영신, 김병수, 최의진pp. 356-361Infectious Mononucleosis Hepatitis in Young Adults: Two Case Reports정규원, 강민정, 유권, 심기남, 조민선, 정성애, 김태훈pp. 381-387Delayed Rupture of the Right Sinus of Valsalva into the Right Atrium after Percutaneous Coronary Intervention임도선, 박승미, 임상엽, 심완주, 홍순준, 신성용, 주형준pp. 388-392
원문 보기